Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 632 participants.
Also called NCT07735130
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 632 participants
- Registry
-
NCT07735130
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07735130. Randomized; no masking; primary purpose treatment. Start 2026-08-15 (anticipated); primary completion 2030-06-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)
- Acronym
- ARBITAR
- Condition
- Left Ventricular Hypertrophy
- Condition
- Severe Aortic Stenosis
- Intervention (Drug)
- Angiotensin Receptor Blocker (ARB)
- Lead sponsor
- Seoul National University Hospital
- Collaborator
- Samjin Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07735130- Content hash
6e8976327086c2bdcd0a03fef907df3a0f0a1903f7786b2862b46ce258eef1b6